Peginterferon beta-1a 63 mcg in 0.5 mL (1) Prefilled Syringe / peginterferon beta-1a 94 mcg in 0.5 mL (1) Prefilled Syringe Pack
RxNorm 1546197

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 1546197 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: peginterferon beta-1a 63 mcg in 0.5 mL (1) Prefilled Syringe / peginterferon beta-1a 94 mcg in 0.5 mL (1) Prefilled Syringe Pack.

The following semantic concepts and normalized strings are associated with this clinical entity:

PSN
Peginterferon beta-1a 63 mcg in 0.5 mL (1) Prefilled Syringe / peginterferon beta-1a 94 mcg in 0.5 mL (1) Prefilled Syringe Pack
AUI:8238434
GPCK
{1 (0.5 mL peginterferon beta-1a 0.126 mg/ML Prefilled Syringe) / 1 (0.5 mL peginterferon beta-1a 0.188 mg/ML Prefilled Syringe) } Pack
AUI:6397025

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

PSNPrescribable

Prescribable Name (PSN):
Peginterferon beta-1a 63 mcg in 0.5 mL (1) Prefilled Syringe / peginterferon beta-1a 94 mcg in 0.5 mL (1) Prefilled Syringe Pack
(Atom ID: 8238434)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
peginterferon beta-1a 63 MCG in 0.5 ML (1) Prefilled Syringe / peginterferon beta-1a 94 MCG in 0.5 ML (1) Prefilled Syringe Pack
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1546197
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
8238434
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
1546197
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

GPCKPrescribable

Generic Pack (GPCK):
{1 (0.5 mL peginterferon beta-1a 0.126 mg/ML Prefilled Syringe) / 1 (0.5 mL peginterferon beta-1a 0.188 mg/ML Prefilled Syringe) } Pack
(Atom ID: 6397025)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
{1 (0.5 ML peginterferon beta-1a 0.126 MG/ML Prefilled Syringe) / 1 (0.5 ML peginterferon beta-1a 0.188 MG/ML Prefilled Syringe) } Pack
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1546197
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
6397025
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
GPCK
Generic Pack ({# (Ingredient + Strength + Dose Form) / # (Ingredient + Strength + Dose Form)} Pack)
Source Code
1546197
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN HUMAN DRUG
US
Drug available for use in Humans

Patient Education

Peginterferon Alfa-2a Injection


Peginterferon alfa-2a is used alone or in combination with other medications to treat chronic (long-term) hepatitis C infection (swelling of the liver caused by a virus) in people who show signs of liver damage. Peginterferon alfa-2a is also used to treat chronic hepatitis B infection (swelling of the liver caused by a virus) in people who show signs of liver damage. Peginterferon alfa-2a is in a class of medications called interferons. Peginterferon is a combination of interferon and polyethylene glycol, which helps the interferon stay active in your body for a longer period of time. Peginterferon works by decreasing the amount of hepatitis C virus (HCV) or hepatitis B virus (HBV) in the body. Peginterferon alfa-2a may not cure hepatitis C or hepatitis B or prevent you from developing complications of hepatitis C or hepatitis B such as cirrhosis (scarring) of the liver, liver failure, or liver cancer. Peginterferon alfa-2a may not prevent the spread of hepatitis C or hepatitis B to other people.
[Learn More]


Peginterferon Beta-1a Injection


Peginterferon beta-1a injection is used to treat adults with various forms of multiple sclerosis (MS; a disease in which the nerves do not function properly and people may experience weakness, numbness, loss of muscle coordination, and problems with vision, speech, and bladder control) including the following: clinically isolated syndrome (CIS; nerve symptom episodes that last at least 24 hours), relapsing-remitting forms (course of disease where symptoms flare up from time to time), or secondary progressive forms (course of disease where relapses occur more often). Peginterferon beta-1a injection is in a class of medications called immunomodulators. It works by decreasing inflammation and preventing nerve damage that may cause symptoms of multiple sclerosis.
[Learn More]


Cancer Chemotherapy


Normally, your cells grow and die in a controlled way. Cancer cells keep growing without control. Chemotherapy is drug therapy for cancer. It works by killing the cancer cells, stopping them from spreading, or slowing their growth. However, it can also harm healthy cells, which causes side effects.

You may have a lot of side effects, some, or none at all. It depends on the type and amount of chemotherapy you get and how your body reacts. Some common side effects are fatigue, nausea, vomiting, pain, and hair loss. There are ways to prevent or control some side effects. Talk with your health care provider about how to manage them. Healthy cells usually recover after chemotherapy is over, so most side effects gradually go away.

Your treatment plan will depend on the cancer type, the chemotherapy drugs used, the treatment goal, and how your body responds. Chemotherapy may be given alone or with other treatments. You may get treatment every day, every week, or every month. You may have breaks between treatments so that your body has a chance to build new healthy cells. You might take the drugs by mouth, in a shot, as a cream, or intravenously (by IV).

NIH: National Cancer Institute


[Learn More]


* Please review the disclaimer below.